PI3Kδ-IN-21

• UNSPSC Description:

  PI3Kδ-IN-21 (Compound 31) is a selective inhibitor for phosphoinositide 3-kinases δ (PI3Kδ), with an IC50 of 13.6 nM. PI3Kδ-IN-21 inhibits proliferation and differentation of T cells through PI3K/AKT/mTOR signaling pathway. PI3Kδ-IN-21 exhibits good pharmacokinetic characters in rat model, and attenuates the experimental autoimmune encephalomyelitis in myelin oligodendrocyte glycoprotein (MOG)-induced EAE model[1].

• Target Antigen:

  PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pi3kδ-in-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@H](C1=CN(C2=CC(Cl)=CN=C21)C3=CC=CN=C3)NC4=NC(N)=NC(N)=C4C#N

• Molecular Weight:

  405.84

• References & Citations:

  [1]Yu M, et al. “Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.” Journal of medicinal chemistry, 10.1021/acs.jmedchem.4c00788. 16 May. 2024,

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported